Clinical Relevance of Intratumoural Immune Cell Composition in Non-Small Cell Lung Cancer.

Xuetao Li,Jia-Tao Zhang,Jian Su,Jinji Yang,Wenzhao Zhong,Xuchao Zhang,Yi-Long Wu,Jun Hou
DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.8547
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:8547 Background: While the understanding of immune landscape of NSCLC has been greatly improved, it is largely unknown how local repertoire of tumor infiltrating leukocytes differs in context of tumor genomics and impacts on prognosis and response to immunotherapy. The aim of this study was to deconvolve immune cell fractions from bulk tissue gene expression profiles (GEPs), and to determine the distinct immune cell composition in molecular subgroups of NSCLC. Methods: Bulk GEPs of 1692 tumor samples of NSCLC patients with known clinical information were obtained from GEO. CIBERSORT algorithm was used to infer the relative proportions of 22 human leukocyte subsets in each tumor. The common and specific immune infiltrating patterns were established for histological and genomic subgroups of NSCLC defined by driver gene mutations. The correlation between intratumoural immune profiles and overall survival (OS) was assessed using multivariable Cox regression model. Results: An increased fraction of regulatory T cells (p < 0.001) and a decreased fraction of plasma cells (PCs) (p < 0.003) were found in advanced NSCLC. With respect to histology, macrophages (Ms) were significant differential cellular component between adenocarcinoma and squamous cell carcinoma. Nevertheless, the high fraction of PCs had longer median OS (8.4 vs 4.4 years, HR 0.59, p = 1e-05) than the low fraction of PCs. The median OS for the low fraction of neutrophils was 7.9 years vs 5.6 years for the high fraction of neutrophils (HR 1.64, p = 0.00072). We found that EGFR-mutant NSCLC was characterized by enriched CD4+ memory resting (CD4mr) (p < 0.0001) and dendritic resting (p < 0.0001) cells, as well as lacking of Ms (p < 0.001). Strikingly, ALK-mutant NSCLC showed a similar intratumoural immune profile with KRAS-mutant NSCLC, illustrated by a low fraction of CD4mr cells and enriched Ms in both molecular subgroups. Conclusions: Our results pointed out the complex relationship between the heterogeneity of intratumoural immune infiltrates, tumor genomics, and patient prognosis across subtypes of NSCLC. Further research is warranted to validate the relation in independent patient cohorts and to explore the impact of immune landscape on immunotherapeutic response.
What problem does this paper attempt to address?